Full history for every metric is available with a Kvantra account
Tharimmune, Inc. (THAR)
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Operating profit | $m | -20 | -54 | |||||
| Net profit | $m | -2 | -2 | -8 | -9 | -12 | -36 | -98 |
| EPS reported | $ | -1.12 | -1.37 | |||||
| Operating cashflow per share | $ | -0.50 | -0.08 | |||||
| Capex per share | $ | 0.00 | 0.25 | |||||
| FCF per share | $ | -0.50 | 0.17 | |||||
| Free cash flow | $m | -16 | 37 | |||||
| Net debt | $m | -17 | -37 | |||||
| Book value equity | $m | 398 | 455 | |||||
| Book value per share | $ | 12.42 | 2.10 | |||||
| Number of shares | m | 32.05 | 216.86 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.24 | 0.31 | |||||
| P/S LTM | x | 0.00 | 93.55 | |||||
| P/FCF LTM | x | -6.02 | 3.77 | |||||
| EV/EBITDA LTM | x | -1.90 | -1.14 | |||||
| EV/Sales LTM | x | 0.00 | 68.65 | |||||
| Earnings Yield LTM | % | -36.99% | -12.78% | |||||
| FCF Yield | % | -16.61% | 26.51% | |||||
| Quality | ||||||||
| ROE | % | -9.03% | -29.54% | |||||
| ROIC | % | -3.32% | -8.14% | |||||
| Operating margin | % | 0.00% | -3595.2% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | 2480.2% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | - | - | |||||
| Net Debt/EBITDA | x | 0.41 | 0.41 | |||||
| EBIT/Net interest | x | -709.33 | -3,921.73 | |||||
| Net debt/market cap | % | -17.54% | -26.61% | |||||
| Net debt/Equity | x | -0.04 | -0.08 | |||||
| Gross debt/equity | x | 0.00 | 0.00 | |||||
Company overview
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Tharimmune, Inc. (THAR)
Tharimmune, Inc. is a biotechnology firm operating in the clinical stage, focused on creating therapeutic solutions for rare, inflammatory, and oncological conditions. Its preclinical immuno-oncology portfolio includes several product candidates: TH104, aimed at treating inflammatory conditions linked to the liver and other causes of itching; TH3215 and TH0059, which are designed to address a variety of solid tumors; and TH1940, specifically targeting programmed cell death protein 1 (PD-1). Furthermore, the company has entered into a research collaboration and product license agreement with Minotaur Therapeutics, Inc. to develop proprietary targeted biologics. Originally incorporated in 2017 as Hillstream BioPharma, Inc., the company rebranded to Tharimmune, Inc. in September 2023 and maintains its headquarters in Bridgewater, New Jersey.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free